HK Stock Market Move | WEIGAO GROUP (01066) fell over 3% as net profit in the first half of the year dropped by 23.23% year-on-year, impacted by price reductions in centralized procurement that dragged down profits in the medical device sector.
Wego Group (01066) fell over 3%. As of the time of publication, it dropped 3.59% to HK$3.355, with a trading volume of HK$92.9396 million.
WEIGAO GROUP (01066) fell over 3%, closing at a drop of 3.59% at HK$3.355, with a transaction amount of HK$92.9396 million.
In terms of news, WEIGAO GROUP released its interim results for 2026, reporting revenue of 6.849 billion yuan, an increase of 3.08% year-on-year; the profit attributable to equity holders was 774 million yuan, representing a decrease of 23.23% year-on-year; after excluding foreign exchange and one-time items, it decreased by 11.7% year-on-year. A midterm dividend of 0.0854 yuan per share is proposed, compared to 0.0969 yuan for the same period last year.
During the period, the turnover of medical device products was approximately 3.364 billion yuan, an increase of 5.4% compared to the same period last year. Although there was revenue growth, the operating profit experienced a nearly 10% year-on-year decline due to price reductions on several core products as a result of centralized procurement policies starting from the third quarter of 2025.
Related Articles

HK Stock Market Move | JST GROUP (06687) rose over 7% during trading hours. JST GROUP officially announced its elevation to a top partner of Meta.

China Securities Co., Ltd.: The fresh snack sector is currently experiencing a surge in stores, and leading brands are expected to stand out in the competition.

Goldman Sachs: Cuts the target price of SINOPHARM (01099) to HKD 18.46, second quarter results meet expectations.
HK Stock Market Move | JST GROUP (06687) rose over 7% during trading hours. JST GROUP officially announced its elevation to a top partner of Meta.

China Securities Co., Ltd.: The fresh snack sector is currently experiencing a surge in stores, and leading brands are expected to stand out in the competition.

Goldman Sachs: Cuts the target price of SINOPHARM (01099) to HKD 18.46, second quarter results meet expectations.

RECOMMEND





